Urgent Call for Universal Diabetes Care in Europe Amidst Political Apathy

By João L. Carapinha

November 25, 2024

The article from Euractiv titled “Universal access to diabetes care urgently needed in Europe, but political will is lacking” highlights several critical issues and recommendations regarding diabetes care in Europe. The growing challenge of diabetes across the continent highlights the urgent need for universal access to diabetes care. With 32 million people living with diabetes, one-third of whom remain undiagnosed, the situation demands immediate attention and action.

Current State of Diabetes Care in Europe

The article emphasizes that diabetes is a significant and growing health challenge in Europe, affecting millions and indicating a pressing need for universal access to diabetes care.

Lack of Political Will

Despite the severity of the issue, there is a lack of sufficient political will to address diabetes comprehensively. While there is growing awareness and enthusiasm from MEPs, more must be done to ensure that diabetes receives the prioritization it needs within the European health agenda.

Key Objectives of IDF Europe

The International Diabetes Federation (IDF) Europe has three main priorities:

– Keeping the person living with diabetes at the center of all efforts.
– Advocacy to increase awareness and push for stronger prioritization of diabetes within the EU’s health agenda.
– Ensuring universal access to diabetes care, including advanced treatments like continuous glucose monitoring (CGM).

Advocacy and Partnerships

IDF Europe is working in partnership with organizations like the World Health Organization (WHO) Europe to amplify their collective voice and achieve impactful outcomes. Their aim is to unite various groups and build advocates within health systems to ensure universal access to diabetes care for all individuals.

Financial and Resource Challenges

The financial burden of diabetes on health systems is substantial. A significant portion of healthcare budgets are allocated to medications and managing complications. Also, the socio-economic impact, including loss of productivity, is significant.

Calls to Action

IDF Europe is calling for politicians to invest in prevention and early treatment to avert costly and devastating complications. Achieving universal access to diabetes care requires not just financial resources but also a committed effort to place diabetes at the forefront of the European agenda.

Need for Comprehensive Plans

There is a pressing need for a structured plan to turn promises into tangible actions. While resolutions and declarations have been made, a comprehensive approach is necessary to ensure targets for diabetes care are met in the medium to long term.

Healthcare System Improvements

Improving access to healthcare services, medicines, and technologies is crucial. This includes strengthening primary care systems, allocating resources more efficiently, and ensuring uninterrupted and affordable access to necessary treatments and tools.

In summary, the article emphasises the urgent need for universal access to diabetes care in Europe. It identifies gaps in the current healthcare systems, and emphasizes the necessity for strong political will. It also notes that comprehensive plans are needed to effectively tackle the escalating diabetes crisis. Universal access to diabetes care is essential for improving health outcomes across Europe.

Reference url

Recent Posts

universal diabetes care
      

Urgent Call for Universal Diabetes Care in Europe Amidst Political Apathy

🌍 Are we doing enough to tackle the diabetes crisis in Europe?

A recent article from Euractiv highlights the urgent need for universal access to diabetes care amidst a growing health challenge affecting millions. With rising cases and a lack of political will, now is the time for action!

Discover the key priorities and recommendations aimed at ensuring equitable care for all individuals living with diabetes.

Read more about how we can advocate for change and improve health outcomes across Europe.

#SyenzaNews #healthcare #universalhealthcoverage #HealthcareInnovation #healthcarepolicy 🌱

340B Drug Pricing Lawsuit
      

Lawsuits Challenge 340B Drug Pricing Program: Eli Lilly and J&J vs. HRSA

🤔 How will ongoing legal battles shape the future of the 340B Drug Pricing Program?

Eli Lilly and Johnson & Johnson are challenging HRSA’s proposed rebate models, arguing that their approaches are essential for enhancing transparency and ensuring discounts directly benefit vulnerable patients. This crucial legal dispute highlights the tensions surrounding drug pricing regulations and could profoundly impact how discounts are provided to covered entities.

Dive into the details of these lawsuits and their implications for the pharmaceutical landscape.

#SyenzaNews #pharmaceuticals #healthcarepolicy #innovation #DrugPricing

WHO Investment Round 2023
    

WHO Investment Round: Securing Funding with Transparency Challenges

🌍 How can global health initiatives thrive with increased funding?

The WHO Investment Round is a pivotal initiative striving to secure $7.1 billion for essential health programs from 2025 to 2028. While achieving 53% of this target via diverse donor engagement, transparency in funding remains a challenge. Discover how these efforts can accelerate progress towards universal health coverage and tackle critical health issues like malaria and cervical cancer!

#SyenzaNews #globalhealth #universalhealthcoverage #healthcare #innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.